Safety and Efficacy of Hair Stimulating Complex (HSC) on Hair Growth in Males With Androgenetic Alopecia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1/PHASE2

Total Enrollment

56 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-12-31

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety and efficacy in relation to dosing in the administration of Hair Stimulating Complex (HSC) in healthy men. HSC will be injected intradermally in the scalps of men with male pattern baldness (i.e. androgenetic alopecia).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of HST 001 in Male Pattern Hair Loss

NCT04435847

Male Pattern Hair Loss

COMPLETED PHASE1

Safety and Tolerability of Hair Stimulating Complex (HSC) in Female Pattern Hair Loss

NCT03662854

Alopecia

UNKNOWN PHASE1

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004512)

NCT01451125

Androgenetic Alopecia Male Pattern Baldness Female Pattern Baldness

COMPLETED PHASE2

Adipose-derived Stem Cell Conditioned Media as a Novel Approach for Hair Regrowth in Male Androgenetic Alopecia

NCT05296863

Alopecia, Androgenetic Hair Loss/Baldness

COMPLETED PHASE3

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002899)

NCT01451112

Androgenetic Alopecia Male Pattern Baldness Female Pattern Baldness

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

HSC consists of proteins secreted by human dermal cells under proprietary culture conditions that include reduced oxygen and bioreactors. Under these conditions, the cells secrete soluble proteins that include both growth factors and soluble precursors to the deposited extracellular matrix. Several of these proteins are known to be important in the control of the hair cycle and will stimulate resting hair follicles to resume hair formation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Androgenetic Alopecia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HSC- Hair Stimulating Complex

Hair Stimulating Complex will be injected intradermally into the scalp of the test subject at 2 timepoints (Baseline and 6 Weeks after Baseline) using sterile syringes with 30 gauge needles at a volume of 0.1 mL per injection. A total of 8 injections (about 3mm apart) will be administered into one of the the 2 randomized sites (left or right) of the subject's scalp. Six weeks after the Baseline injection, the same treatment site will receive a repeat dose (the same volume and number of injections as used in the baseline) with no crossover.

Group Type EXPERIMENTAL

Hair Stimulating Complex (HSC)

Intervention Type BIOLOGICAL

Study preparation (experimental) of 0.8 mL will be injected intradermally at Baseline and Week 6.

Dulbecco's Modified Eagle Medium, DMEM

Dulbecco's Modified Eagle Medium (DMEM) will be administered the same way as described above into treatment zone of the test subject's scalp not treated with HSC.

Group Type PLACEBO_COMPARATOR

Dulbecco's Modified Eagle Medium, DMEM

Intervention Type DEVICE

Study preparation (placebo comparator) of 0.8 mL will be injected intradermally at Baseline and Week 6.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hair Stimulating Complex (HSC)

Study preparation (experimental) of 0.8 mL will be injected intradermally at Baseline and Week 6.

Intervention Type BIOLOGICAL

Dulbecco's Modified Eagle Medium, DMEM

Study preparation (placebo comparator) of 0.8 mL will be injected intradermally at Baseline and Week 6.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male, ages 21-65 years.
2. A healthy scalp with no cutaneous disorder.
3. Subject should be in good general health.
4. Male subjects must be classified 3 Vertex, 4, 4A (if large enough), 5, 5A, or 6 under the Norwood-Hamilton Classification for Male Pattern Hair Loss (See Appendix 1).
5. Subject must be Fitzpatrick Type I, II, III and IV skin pigmentation (See Appendix 2). Type IV is acceptable however Type I-III is preferable.
6. Willing and able to comply with scheduled visits (Total: 7 visits in 48 weeks)
7. Willing to maintain the same hair style during the study period.
8. Willing to have a total of four microscopic dot tattoos. Two tattoos per treatment site (one in the center and one on the edge) of the two target regions of the scalp at miniaturization zone.
9. Willing to have 2 cm2 hairs clipped at treatment areas.
10. Willing to forgo the use of scalp products, including dye, throughout the study except for study related dye.
11. Willing to use a mild, a non-ionic shampoo throughout the course of the study.

Exclusion Criteria

1. History of keloid formation or hyperpigmentation.
2. A history of any acute or chronic illness that in the opinion of the investigators might confound the results of the study including some drugs or medications.
3. Active skin diseases (e.g. eczema, atopic dermatitis, psoriasis, skin cancer, sun damaged skin with actinic keratosis on scalp, etc.).
4. Routine high dosage use of anti-inflammatory medications (aspirin, ibuprofen, corticosteroids), immunosuppressive drugs or antihistamine medications (steroid nose drops and/or eye drops are permitted). Two 81 mg or one 325 mg aspirin per day is also acceptable.
5. Use of topical drugs or other cosmetics on the scalp.
6. Immunological disorders such as HIV positive, alopecia areata, and systemic lupus erythematosus.
7. Participation in any clinical study within the last four weeks.
8. Moderate or severe seborrheic dermatitis of scalp.
9. Damaged skin in or around test sites including sunburn, uneven skin tones, tattoos, scars or other disfiguration of the test site.
10. Use of OTC (over-the-counter) or prescriptive topical or hair treatments, as well as hair transplantation surgery during the last 6 months. This includes Minoxidil 2% or 5% and/or Finasteride 1mg or any 5alpha-reductase inhibitors.
11. Currently using hair system or wig.
12. Presence of hair transplants or scalp surgery.
13. History of allergy or intolerance to lidocaine and/or epinephrine.
14. Use of hair dye (not study related) during the study duration.
15. Any condition for which the Investigator determines that the subject could be placed under undue risk.
16. Reported history of allergy or intolerance to bovine proteins.

Minimum Eligible Age

21 Years

Maximum Eligible Age

65 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes